Barclays initiated coverage of Altimmune (ALT) with an Overweight rating and $20 price target
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALT:
- Altimmune call volume above normal and directionally bullish
- Unusually active option classes on open January 22nd
- Enovix, Serve Robotics, EOG, Altimmune, Globalstar Shake Markets
- Midday Fly By: U.S. oil majors rise on Venezuela news, Versant completes spinoff
- Altimmune receives FDA breakthrough therapy designation for pemvidutide